Pharma Stocks
-
Is its oncology dominance strong enough to unl
As China’s leading innovative drug developer, Jiangsu Hengrui excels in oncology and beyond, but can its R&D firepower sustain growth…
Read More » -
Is It Too Late To Consider Phibro Animal Health (PAHC) After Its 235% One-Year Surge?
If you are wondering whether Phibro Animal Health’s share price still makes sense after a big run, this article walks…
Read More » -
Is its CDMO dominance strong enough to unlock new ups
As a leading contract development and manufacturing organization, Samsung Biologics drives growth through global biopharma partnerships that matter to your…
Read More » -
Stocks to Watch for April13: Muthoot Finance, Mahindra & Mahindra, Torrent Pharma and more
From Muthoot Finance approving ₹30 interim dividend to Mahindra & Mahindra reporting higher March 2026 production and sales, here are…
Read More » -
Is It Too Late To Consider Jazz Pharmaceuticals (JAZZ) After A 93% One Year Rally?
If you are wondering whether Jazz Pharmaceuticals at around US$194.20 is still offering value after a strong run, the key…
Read More » -
Is Leqembi success strong enough to unlock new upside?
Eisai’s Alzheimer’s breakthrough Leqembi offers U.S. investors exposure to a massive unmet need in neurology. With Biogen partnership driving global…
Read More » -
Is Leqembi success strong enough to unlock new upside?
Eisai’s Alzheimer’s breakthrough Leqembi offers U.S. investors exposure to a massive unmet need in neurology. With Biogen partnership driving global…
Read More » -
New to The Street Broadcasts on Bloomberg Television at 6:30 PM EST Featuring IGC Pharma (IGC), Vivos Therapeutics (VVOS), Acurx Pharmaceuticals (ACXP), and Equinox Gold (EQX)
Special continuing M&A Segment with Senior M&A Partner at Sullivan & Cromwell LLP, Frank Aquila NEW YORK CITY, NY /…
Read More » -
UroGen Pharma (URGN) Is Up 14.6% After Phase 3 ENVISION Data And LG-UTUC Outreach Push
In late March and early April 2026, UroGen Pharma announced publication of pivotal Phase 3 ENVISION data for bladder cancer…
Read More » -
Merck’s Eye Drug Trial Adds New Dimension To Growth And Valuation Narrative
Merck (NYSE:MRK) has started a pivotal Phase 2b/3 trial for MK-8748, also known as Tiespectus, in neovascular age related macular…
Read More »